H.C. Wainwright Raised Its Price Target on ImmunityBio, Inc. (IBRX) to $15 from $10 and Maintains a Buy Rating

On February 23, 2026, H.C. Wainwright raised its terms people connected ImmunityBio, Inc. (NASDAQ:IBRX) to $15 from $10 and maintained a Buy standing connected the shares. The expert said the caller European Union support expands Anktiva’s footprint to 33 countries, “removing a large regulatory overhang” and opening a “meaningful incremental commercialized opportunity.”

That aforesaid day, ImmunityBio reported Q4 EPS of (6c), compared to the (10c) statement estimate. Q4 gross was $38.29M versus statement of $37.78M. President and CEO Richard Adcock said the company’s 2025 fiscal results bespeak the increasing objective adoption of Anktiva “as a foundational backbone of immunotherapy for bladder cancer.” He noted that the concern with Accord Healthcare deploys implicit 100 commercialized professionals crossed 30 European countries and that collaboration with BioPharma & Cigalah supports commercialized execution successful Saudi Arabia and the broader MENA region. Adcock stated that with subsidiaries successful Dublin and the Kingdom of Saudi Arabia, the institution has infrastructure to enactment maturation crossed each 33 countries wherever Anktiva is authorized. He added that the institution remains focused connected completing enrollment successful its BCG-naive randomized proceedings with a BLA filing targeted by Q4 2026, expanding the Anktiva statement into lung crab and lymphopenia, and converting its “700% gross maturation trajectory” into durable worth for shareholders.

ImmunityBio, Inc. (NASDAQ:IBRX) is simply a biotechnology institution focused connected processing and commercializing next-generation immunotherapies for crab and infectious diseases.

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey connected Google News.